380 related articles for article (PubMed ID: 31257247)
21. Prominent microglial inclusions in transgenic mouse models of α-synucleinopathy that are distinct from neuronal lesions.
Tanriöver G; Bacioglu M; Schweighauser M; Mahler J; Wegenast-Braun BM; Skodras A; Obermüller U; Barth M; Kronenberg-Versteeg D; Nilsson KPR; Shimshek DR; Kahle PJ; Eisele YS; Jucker M
Acta Neuropathol Commun; 2020 Aug; 8(1):133. PubMed ID: 32787922
[TBL] [Abstract][Full Text] [Related]
22. α-Synuclein Conformational Plasticity: Physiologic States, Pathologic Strains, and Biotechnological Applications.
Li A; Rastegar C; Mao X
Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883550
[TBL] [Abstract][Full Text] [Related]
23. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
24. Dissecting α-synuclein inclusion pathology diversity in multiple system atrophy: implications for the prion-like transmission hypothesis.
Dhillon JS; Trejo-Lopez JA; Riffe C; McFarland NR; Hiser WM; Giasson BI; Yachnis AT
Lab Invest; 2019 Jul; 99(7):982-992. PubMed ID: 30737468
[TBL] [Abstract][Full Text] [Related]
25. Distinct mechanisms of axonal globule formation in mice expressing human wild type α-synuclein or dementia with Lewy bodies-linked P123H β-synuclein.
Sekigawa A; Fujita M; Sekiyama K; Takamatsu Y; Hatano T; Rockenstein E; La Spada AR; Masliah E; Hashimoto M
Mol Brain; 2012 Sep; 5():34. PubMed ID: 23013868
[TBL] [Abstract][Full Text] [Related]
26. Cellular processing of α-synuclein fibrils results in distinct physiological C-terminal truncations with a major cleavage site at residue Glu 114.
Quintin S; Lloyd GM; Paterno G; Xia Y; Sorrentino Z; Bell BM; Gorion KM; Lee EB; Prokop S; Giasson BI
J Biol Chem; 2023 Jul; 299(7):104912. PubMed ID: 37307916
[TBL] [Abstract][Full Text] [Related]
27. Alpha-synucleinopathies.
Alafuzoff I; Hartikainen P
Handb Clin Neurol; 2017; 145():339-353. PubMed ID: 28987181
[TBL] [Abstract][Full Text] [Related]
28. Are synucleinopathies prion-like disorders?
Angot E; Steiner JA; Hansen C; Li JY; Brundin P
Lancet Neurol; 2010 Nov; 9(11):1128-38. PubMed ID: 20846907
[TBL] [Abstract][Full Text] [Related]
29. Induction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synuclein.
Sacino AN; Brooks M; McGarvey NH; McKinney AB; Thomas MA; Levites Y; Ran Y; Golde TE; Giasson BI
Acta Neuropathol Commun; 2013 Jul; 1():38. PubMed ID: 24252149
[TBL] [Abstract][Full Text] [Related]
30. ɑ-Synuclein strains and seeding in Parkinson's disease, incidental Lewy body disease, dementia with Lewy bodies and multiple system atrophy: similarities and differences.
Peelaerts W; Bousset L; Baekelandt V; Melki R
Cell Tissue Res; 2018 Jul; 373(1):195-212. PubMed ID: 29704213
[TBL] [Abstract][Full Text] [Related]
31. Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies.
Sharon R; Bar-Joseph I; Mirick GE; Serhan CN; Selkoe DJ
J Biol Chem; 2003 Dec; 278(50):49874-81. PubMed ID: 14507911
[TBL] [Abstract][Full Text] [Related]
32. Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.
Uchihara T; Giasson BI
Acta Neuropathol; 2016 Jan; 131(1):49-73. PubMed ID: 26446103
[TBL] [Abstract][Full Text] [Related]
33. Neural connectivity predicts spreading of alpha-synuclein pathology in fibril-injected mouse models: Involvement of retrograde and anterograde axonal propagation.
Mezias C; Rey N; Brundin P; Raj A
Neurobiol Dis; 2020 Feb; 134():104623. PubMed ID: 31628991
[TBL] [Abstract][Full Text] [Related]
34. Potent prion-like behaviors of pathogenic α-synuclein and evaluation of inactivation methods.
Tarutani A; Arai T; Murayama S; Hisanaga SI; Hasegawa M
Acta Neuropathol Commun; 2018 Apr; 6(1):29. PubMed ID: 29669601
[TBL] [Abstract][Full Text] [Related]
35. Copper and iron ions accelerate the prion-like propagation of α-synuclein: A vicious cycle in Parkinson's disease.
Li Y; Yang C; Wang S; Yang D; Zhang Y; Xu L; Ma L; Zheng J; Petersen RB; Zheng L; Chen H; Huang K
Int J Biol Macromol; 2020 Nov; 163():562-573. PubMed ID: 32629061
[TBL] [Abstract][Full Text] [Related]
36. ɑ-Synuclein strains and the variable pathologies of synucleinopathies.
Peelaerts W; Baekelandt V
J Neurochem; 2016 Oct; 139 Suppl 1():256-274. PubMed ID: 26924014
[TBL] [Abstract][Full Text] [Related]
37. The prion hypothesis of Parkinson's disease.
Chu Y; Kordower JH
Curr Neurol Neurosci Rep; 2015 May; 15(5):28. PubMed ID: 25868519
[TBL] [Abstract][Full Text] [Related]
38. The prion-like spreading of α-synuclein: From in vitro to in vivo models of Parkinson's disease.
Vargas JY; Grudina C; Zurzolo C
Ageing Res Rev; 2019 Mar; 50():89-101. PubMed ID: 30690184
[TBL] [Abstract][Full Text] [Related]
39. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies.
Neumann M; Kahle PJ; Giasson BI; Ozmen L; Borroni E; Spooren W; Müller V; Odoy S; Fujiwara H; Hasegawa M; Iwatsubo T; Trojanowski JQ; Kretzschmar HA; Haass C
J Clin Invest; 2002 Nov; 110(10):1429-39. PubMed ID: 12438441
[TBL] [Abstract][Full Text] [Related]
40. The concept of alpha-synuclein as a prion-like protein: ten years after.
Steiner JA; Quansah E; Brundin P
Cell Tissue Res; 2018 Jul; 373(1):161-173. PubMed ID: 29480459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
